TCL Archive Cancer Groups Fear Clinical Trials Coverage Will Not Be Implemented Across Exchanges July 3, 2013
TCL Archive Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone April 10, 1987
TCL Archive Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment. July 30, 2004
